Investors In Indivior Celebrated After The Pharmaceuticals Group And Its Former Parent Company Reckitt Benckiser Put An End To A Bitter And Costly Legal Battle

Investors in Indivior celebrated after the pharmaceuticals group and its former parent company Reckitt Benckiser put an end to a bitter and costly legal battle.
Dettol-maker Reckitt has dropped a £1billion claim related to a US probe after Indivior agreed to pay it £36million over the next five years. 
Both have also agreed to drop all liabilities against one another in a settlement that will save them millions in legal costs.
Lawsuit: Indivior has spent years wrangling with US authorities, who accused the company of fraudulently marketing its bestselling opioid addiction treatment suboxone
Indivior has spent years wrangling with US authorities, panel sosmed termurah who accused it of fraudulently marketing its best-selling opioid addiction treatment suboxone by underplaying safety risks. 
It is one of the few corporate prosecutions related to the US prescription opioid epidemic, which has been blamed for hundreds of thousands of overdose deaths.
RELATED ARTICLES Share this article Share HOW THIS IS MONEY CAN HELP Last year Indivior agreed to pay £440million to settle the case and a former boss pleaded guilty to fraud charges, landing him jail time and fines. 
Indivior was spun out of Reckitt in 2014 - but because a lot of the charges related to actions carried out before the separation, Reckitt also faced lawsuits and eventually reached a £1billion settlement with US authorities last year.
<div class="art-ins mol-factbox floatRHS money" data-version="2" id="mol-6868a2d0-5ffb-11eb-8dc8-53a260c8516c" website REPORT: Indivior soars as it settles legal battle with Reckitt